Year archive

ARGENICA THERAPEUTICS LIMITED — 2025 filings

All 52 regulatory filings released by ARGENICA THERAPEUTICS LIMITED (AGN) in 2025, sourced directly from the official regulator.

52 Filings

2025 Period

2025 filings (52)

Filing	Released	Lang
Non-Executive Chair Resignation 1 page 186.0KB Board/Management Information	2025-12-28	English
AI Analysis Reveals Efficacy In Severe Stroke Patients 9 pages 437.3KB Regulatory Filings	2025-12-10	English
Positive TNK Study Results Fulfil Key FDA Requirement 3 pages 325.2KB Capital/Financing Update	2025-12-03	English
ARG-007 Efficacious Dose Validated in New Preclinical Study 5 pages 351.3KB Regulatory Filings	2025-11-24	English
Non-Executive Director Retirement 1 page 206.1KB Board/Management Information	2025-11-11	English
AGM Chair's Address & Presentation 28 pages 3.0MB AGM Information	2025-11-11	English
Results of Annual General Meeting 2 pages 275.9KB Declaration of Voting Results & Voting Rights Announcements	2025-11-11	English
Final Director's Interest Notice 2 pages 306.7KB Director's Dealing	2025-11-11	English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 491.5KB Interim / Quarterly Report Q1 2026	2025-10-30	English
Investor Presentation - Cannacord Dug & Device Conference 18 pages 2.4MB Investor Presentation	2025-10-20	English
Notification regarding unquoted securities - AGN 7 pages 21.1KB Share Issue/Capital Change	2025-10-19	English
Phase 2 Trial Promising Improvements in Functional Outcomes 5 pages 468.9KB Capital/Financing Update	2025-10-14	English
Notice of Annual General Meeting/Proxy Form 17 pages 639.0KB AGM Information	2025-10-12	English
ASX Small Caps Conference Presentation 19 pages 2.4MB Investor Presentation	2025-09-23	English
Date of AGM & Closing Date for Director Nominations 1 AGM Information	2025-09-16	English
Change in substantial holding 3 pages 222.1KB Major Shareholding Notification	2025-09-03	English
Topline Phase 2 Trial Results of ARG-007 in AIS Patients 7 pages 391.8KB Capital/Financing Update	2025-09-02	English
Investor Presentation 16 pages 1.4MB Investor Presentation	2025-09-02	English
Investor Webinar 1 page 201.2KB Investor Presentation	2025-09-02	English
Trading Halt 2 pages 301.7KB Regulatory Filings	2025-08-31	English
Appendix 4E & Annual Report to 30 June 2025 52 pages 2.5MB Annual Report FY 2025	2025-08-27	English
Appendix 4G & Corporate Governance Statement 24 pages 687.1KB Regulatory Filings	2025-08-27	English
Argenica Receives IND Feedback From FDA 3 pages 266.3KB Regulatory Filings	2025-08-13	English
Bioshares Biotech Summit Presentation 20 pages 2.4MB Investor Presentation	2025-08-07	English
Argenica Appoints Vice President of Regulatory Affairs 2 pages 205.9KB Board/Management Information	2025-08-05	English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 501.0KB Interim / Quarterly Report Q4 2025	2025-07-22	English
Ceasing to be a substantial holder from IFL 2 pages 59.7KB Major Shareholding Notification	2025-07-22	English
Application for quotation of securities - AGN 6 pages 18.5KB Share Issue/Capital Change	2025-07-08	English
Notification of cessation of securities - AGN 4 pages 14.8KB Share Issue/Capital Change	2025-07-08	English
Application for quotation of securities - AGN 6 pages 19.1KB Share Issue/Capital Change	2025-07-08	English
Cleansing Notice 1 page 189.2KB Regulatory Filings	2025-07-08	English
Argenica Awarded Federal Government Funding 2 pages 280.2KB Capital/Financing Update	2025-06-19	English
Argenica to Progress Clinical Development in TBI 9 pages 484.8KB Capital/Financing Update	2025-06-17	English
Update on Investigational New Drug Application 2 pages 217.6KB Regulatory Filings	2025-06-09	English
Notification regarding unquoted securities - AGN 6 pages 20.5KB Share Issue/Capital Change	2025-06-02	English
Notification of cessation of securities - AGN 4 pages 14.8KB Share Issue/Capital Change	2025-06-02	English
Change of Director's Interest Notice 3 pages 264.7KB Director's Dealing	2025-06-02	English
Investor Webinar 1 page 202.7KB Investor Presentation	2025-05-22	English
New US Patent for Surgical Stroke 2 pages 205.9KB Regulatory Filings	2025-05-21	English
Investor Presentation 25 pages 2.6MB Investor Presentation	2025-05-18	English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 486.6KB Interim / Quarterly Report Q3 2025	2025-04-29	English
Last Patient Dosed in Phase 2 Stroke Trial 2 pages 278.6KB Regulatory Filings	2025-04-10	English
Notification of cessation of securities - AGN 4 pages 14.7KB Share Issue/Capital Change	2025-03-31	English
Change of Share Registry Details 2 pages 183.2KB Regulatory Filings	2025-03-20	English
Investor Presentation 23 pages 2.5MB Investor Presentation	2025-03-11	English
Non-Executive Director Resignation 1 page 196.4KB Board/Management Information	2025-03-02	English
Final Director's Interest Notice 2 pages 308.3KB Director's Dealing	2025-03-02	English
Half Yearly Report and Accounts 17 pages 977.1KB Interim / Quarterly Report H1 2025	2025-02-10	English
ARG-007 Shows Significant Neuroprotection in Main TBI Study 9 pages 511.9KB Regulatory Filings	2025-02-03	English
Updated - Main TBI Injury Study Annoucement 10 pages 522.9KB Regulatory Filings	2025-02-03	English
Positive DSMB Safety Outcome & Phase 2 Trial Progress Update 3 pages 323.3KB Capital/Financing Update	2025-01-29	English
Quarterly Activities/Appendix 4C Cash Flow Report 12 pages 533.9KB Interim / Quarterly Report H1 2025	2025-01-29	English